1. Generics Bulletin
  2. >>Business
  3. >>Deals

Viatris To Shed OTC, APIs And Women’s Health As Biocon Deal Nears Completion

Expecting Further $5bn-$6bn In Pre-Tax Proceeds, As Two Acquisitions Announced

 
• By Dean Rudge

Viatris has marked an important inflection point in its short life, announcing several more planned divestitures alongside the proposed acquisition of a pair of eyecare companies for up to $750m in cash.

Feodora Chiosea/Alamy Stock Vector
Viatris is aiming to generate up to $9bn in pre-tax proceeds • Source: Shutterstock (Feodora Chiosea / Alamy Stock Ve/Alamy Stock Vector)

Viatris has named four more businesses planned for the auction block under its proposed $9bn global overhaul, as the $3.3bn agreement to offload the firm’s global biosimilars unit to Biocon Biologics nears completion.

The combination of the former Mylan and Upjohn businesses is readying the second phase of its growth strategy beginning in 2024, announcing on 7 November that it would use some of the expected divestiture proceeds to acquire ophthalmology players

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Teva And Alvotech Celebrate Interchangeability For US Ustekinumab

 
• By Dave Wallace

The market for biosimilar rivals to Stelara continues to be hotly contested in the US, with partners Teva and Alvotech claiming a boost from an interchangeability designation at the same time as Biocon Biologics highlighted fresh market access agreements.

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition

 
• By Dean Rudge

Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By Dave Wallace

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.